Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development Aug 7, 2019
Ocuphire Pharma Raises Over $5 Million to Complete Multiple Late Phase 2 Clinical Trials Jul 22, 2019
Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China Apr 16, 2019
Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting Mar 27, 2019
Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients Mar 4, 2019
